CN1504190A - Pharmaceutical composition containing levo-histidine for treating diabetes - Google Patents
Pharmaceutical composition containing levo-histidine for treating diabetes Download PDFInfo
- Publication number
- CN1504190A CN1504190A CNA021508941A CN02150894A CN1504190A CN 1504190 A CN1504190 A CN 1504190A CN A021508941 A CNA021508941 A CN A021508941A CN 02150894 A CN02150894 A CN 02150894A CN 1504190 A CN1504190 A CN 1504190A
- Authority
- CN
- China
- Prior art keywords
- histidine
- diabetes
- pharmaceutical composition
- zinc
- treating diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a pharmaceutical composition containing L-Histidine for treating diabetes which comprises, (1) a zinc salt, including a zinc positive ion and a negative ion, (2) purified ring group Protide, (3) biguanides hyperglycemia resistant agent, (4) a pharmacologically accepted excipient, and (5) L-histidine. The composition provided by the present invention is effective in treating diabetes.
Description
Technical field:
The present invention relates to field of medicaments, relate in particular to diabetes, is a kind of pharmaceutical composition that is used for the treatment of diabetes that contains l-histidine specifically.
Background technology:
Diabetes are human modal metabolism disorders, major part is to rely on insulin, or be called the diabetes of first type, and also having a kind of is the diabetes that do not rely on insulin, these amphitypy diabetes all can injure health and utilize the ability of glucose as the energy.Chronic hyperglycemia can injure a lot of tissues and the organ of health at leisure.Though can utilize insulin for treating diabetes,, diabetes are still and are required to be a lot of dead serious diseases of being responsible for morbid state in the whole world.The consequence of long-term diabetes, can include eyes impaired, often cause losing one's sight, blood circulation problem, wound healing problem, and other serious consequence, the appearance that studies show that diabetes in recent years is relevant with the zinc ion in the cell.
Summary of the invention:
Technical problem to be solved by this invention is: because in the prior art, there is not effective medicine for treatment of diabetes, can play the purpose of effecting a permanent cure, the present invention is for solving the above-mentioned technical problem in the prior art, the technical scheme that is adopted provides a kind of pharmaceutical composition that is used for the treatment of diabetes that contains l-histidine, described compositions comprises: (1) a kind of zinc salt, zinc salt include zinc cation and a kind of anion; (2) ring Pro of purification; (3) biguanides antihyperglycemic agents; (4) a kind of can received excipient on pharmaceutics; And (5) l-histidine, wherein, weight ratio in the compositions between zinc cation, biguanides antihyperglycemic agents, ring Pro and the l-histidine is at 1-100: 2-100: 1-1000: between the 1-500, anion in the described zinc salt is selected from chloride or sulfate, and described excipient adopts safflower oil, lecithin, inositol, soybean based shortenings, gelatin, arabic gum, glycerol, titanium oxide or the soybean oil in the prior art.Described compositions can be packaged into capsular form, and compositions of the present invention is effective to the treatment diabetes.Clinical research shows: diabetics demonstrate intestinal to the absorption of zinc impaired and blood plasma low zinc content, when using compositions of the present invention, diabetic animal organize zinc content normalization.Therefore, described compositions must promote the more zinc metabolism of normalization of diabetes mouse.
The specific embodiment:
A kind of pharmaceutical composition that is used for the treatment of diabetes that contains l-histidine of the present invention, described compositions comprises: (1) a kind of zinc salt, zinc salt include zinc cation and a kind of anion; (2) ring Pro of purification; (3) biguanides antihyperglycemic agents; And (4) l-histidine, wherein, weight ratio in the compositions between zinc cation, biguanides antihyperglycemic agents, ring Pro and the l-histidine is at 1: 2: 500: between 200, anion in the described zinc salt is selected from chloride, described excipient adopts gelatin, described compositions is packaged into capsular form, and compositions of the present invention is effective to the treatment diabetes.Clinical research shows: diabetics demonstrate intestinal to the absorption of zinc impaired and blood plasma low zinc content; When using compositions of the present invention, diabetic animal organize zinc content normalization.Therefore, described compositions must promote the more zinc metabolism of normalization of diabetes mouse.
Claims (2)
1, a kind of pharmaceutical composition that is used for the treatment of diabetes that contains l-histidine, it is characterized in that: described compositions comprises: (1) a kind of zinc salt, zinc salt include zinc cation and a kind of anion; (2) ring Pro of purification; (3) biguanides antihyperglycemic agents; (4) a kind of can received excipient on pharmaceutics; And (5) l-histidine, wherein, weight ratio in the compositions between zinc cation, biguanides antihyperglycemic agents, ring Pro and the l-histidine is at 1-100: 2-100: 1-1000: between the 1-500, the anion in the described zinc salt is selected from chloride or sulfate.
2, a kind of pharmaceutical composition that is used for the treatment of diabetes that contains l-histidine as claimed in claim 1 is characterized in that: described excipient adopts safflower oil, lecithin, inositol, soybean based shortenings, gelatin, arabic gum, glycerol, titanium oxide or soybean oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021508941A CN1504190A (en) | 2002-12-03 | 2002-12-03 | Pharmaceutical composition containing levo-histidine for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021508941A CN1504190A (en) | 2002-12-03 | 2002-12-03 | Pharmaceutical composition containing levo-histidine for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1504190A true CN1504190A (en) | 2004-06-16 |
Family
ID=34234147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021508941A Pending CN1504190A (en) | 2002-12-03 | 2002-12-03 | Pharmaceutical composition containing levo-histidine for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1504190A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11896581B2 (en) | 2020-09-04 | 2024-02-13 | Société des Produits Nestlé S.A. | Compositions and methods for providing health benefits in an animal |
-
2002
- 2002-12-03 CN CNA021508941A patent/CN1504190A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11896581B2 (en) | 2020-09-04 | 2024-02-13 | Société des Produits Nestlé S.A. | Compositions and methods for providing health benefits in an animal |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2258302T3 (en) | MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AS WELL AS ITS SECONDARY EFFECTS. | |
| US20180051017A1 (en) | Agent for treatment of schizophrenia | |
| EP0621038A1 (en) | Pharmaceutical compositions containing silicate polymers | |
| Nishikawa et al. | Asystole during spinal anaesthesia after change from Trendelenburg to horizontal position | |
| CN1504190A (en) | Pharmaceutical composition containing levo-histidine for treating diabetes | |
| EP2308485A1 (en) | Sulfonamides for the prevention of diabetes | |
| CN1506073A (en) | Application of zinc salt in medicine for treating diabetes | |
| CN1476893A (en) | Medince composition containing huanzupulo for curing diabetes | |
| CN1572304A (en) | Medicinal composition for treating diabetes mellitus containing ring Pro | |
| CN1449823A (en) | Use of ulinastatin in treating SARS and medicinal composition thereof | |
| DE60203895T2 (en) | USE OF N-ACETYL-D-GLUCOSAMINE IN THE MANUFACTURE OF A MEDICAMENT FOR SUPPRESSING THE SIDE EFFECTS OF RADIOTHERAPY AND CHEMOTHERAPY | |
| CN102058523A (en) | Procaine injection | |
| EP3265089B1 (en) | New use of the isoquinoline derivative salsolinol for diabetic wound healing | |
| DK1697401T3 (en) | Tetrapeptide which regulates blood glucose levels in diabetes mellitus | |
| RU2230568C1 (en) | Method for treating phlegmons in oral area | |
| Amit Gupta | REAL-WORLD CLINICAL EFFECTIVENESS AND TOLERABILITY OF HYDROXYCHLOROQUINE 400MG IN T2DM | |
| CN1506048A (en) | Application of levo histidine in treating diabetes | |
| RU2201179C2 (en) | Method for treating diabetic retinopathies | |
| CN100337621C (en) | Application of aspartic acid and its salt | |
| CN1507863A (en) | Use of aza cyclopentane dione derivative for treating diabetes | |
| CN115429788A (en) | Medicine for treating demyelinating diseases and application thereof | |
| CN1507917A (en) | Medicine containing nitric oxide synthase inhibitor for treating diabetes | |
| US20020165281A1 (en) | Treatment of anoxic encephalophathy by administration of N-acetylcystein | |
| EP2051717B1 (en) | Replacing heart surgery by micronutrient | |
| RU2258520C2 (en) | Method for treating stem ischemic insult |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |